Mumbai, : Alkem Laboratories Ltd. has announced an increase in its planned investment to ₹1,036 crore for the expansion of its manufacturing facility in Ujjain, Madhya Pradesh, reinforcing its commitment to strengthening production capacity and supporting long-term growth.

The enhanced investment is aimed at scaling up manufacturing capabilities, upgrading infrastructure, and incorporating advanced technologies to meet the growing demand for pharmaceutical products across domestic and international markets. The Ujjain facility is expected to play a key role in expanding Alkem’s footprint in formulations and specialty products.

According to company officials, the expansion will focus on capacity augmentation, process optimization, and compliance with global quality standards, ensuring the facility is aligned with regulatory requirements across key export markets. The move is also expected to enhance operational efficiency and support the company’s evolving product portfolio.

The increased capital allocation reflects Alkem’s strategic focus on strengthening its manufacturing backbone, improving supply chain resilience, and capitalizing on opportunities in the rapidly growing pharmaceutical sector. The investment is anticipated to generate employment opportunities and contribute to the industrial development of the region.

Industry observers view the development as a strong signal of confidence in India’s pharma manufacturing ecosystem, as companies continue to invest in expanding capabilities to cater to rising global demand and evolving healthcare needs.

With this expansion, Alkem Laboratories aims to further consolidate its position as a leading pharmaceutical player, while continuing to deliver high-quality, affordable medicines across markets.